Our study aims at examining the suitability of Scopus for bibliometric analyses in comparison with the Web of Science (WOS). In particular we want to explore if the outcome of bibliometric analyses differs between Scopus and WOS and, if yes, in which aspects. In doing so we focus on the following questions: To which extent are high impact JCR (Journal Citation Reports) journals covered by Scopus? Are the impact factor and the immediacy index usually lower for a JCR journal than the corresponding indicators computed in Scopus? Are there high impact journals not covered by the JCR? And, finally, how reliable are the data in these two databases?
Introduction
In 2002, David Adam [1] reported in his article in Nature that the Institute for Scientific Information (ISI) was the undisputed king of the counting houses and the indispensable instrument for scientometric purposes and especially for citation analysis. Adam also foresaw that new software scanning articles, extracting references and automatically generating citation indices may challenge ISI's monopoly shortly after. Late in November 2004 Scopus, a research tool from Elsevier Publishing Company, was commercially launched and claimed to be the "world's largest abstract and indexing database" [2] .
The Scopus Web site [3] provides detailed information about the database which has enlisted the collaboration of over 300 researchers world-wide at 21 different institutions for extensive product testing and feedback. In the last two years the product has improved constantly. Scopus has emerged as a dependable research tool providing a user friendly search interface. Furthermore, and even more important, Scopus offers reliable and easy to use citation searching, a feature that until recently has been the exclusive domain of ISI. Actually its new citation tracker has been emulated by its competitor, the Web of Science (WOS), which illustrates the importance and impact this product has gained by now.
There are already several publications which provide more or less extensive evaluations of Scopus with particular emphasis on a comparison with the Web of Science (e. g. Deis & Goodman [4] [5] , Gorraiz [6] ; Jacso [7] , LaGuardia [8] , Pipp [9] , Schneider [10] , Wildner [11] ). Just recently, a comprehensive study has been conducted at Utrecht University Library comparing Scopus, Web of Science and Google Scholar with regards to coverage and functionality [12] . However there are only a few studies which focused on the suitability of these citation databases for scientometric analyses.
In their study which analysed citation counts of the Journal of the American Society for Information Science and Technology (JASIST), Bauer and Bakkalbasi [13] found that the Web of Science provided more citation counts to 1985 articles, although this could not be tested statistically. For JASIST articles published in 2000, there was no significant difference between Web of Science and Scopus. Similar results are reported by Jacso [14] . In a recent publication, Ball and Tunger [15] compare the two databases with regard to the number of articles covered, the areas of interest, the number of non-cited articles, and the number of citations of a set of articles. The authors conclude that the outcome of bibliometric analyses may be quite different depending on the database chosen. The identification of such differences was also at the core of the article by Klavans and Boyack [16] who investigated if Scopus and Web of Science generate maps representing the structure of science that are structurally equivalent.
Research questions and methodology
As already mentioned above, Scopus has emerged as a reliable and easy to use research tool for citation searching. However when it comes up to bibliometric analyses, it seems that Scopus did not yet break the monopoly of its competitor. For this reason, our study aims at examining the suitability of Scopus for bibliometric analyses in comparison with the Web of Science. In particular we want to investigate Scopus and the Web of Science with regard to the following issues:
Since Scopus does not provide any citation statistics comparable to the JCR, we had to retrieve the necessary data from this database manually. But since Scopus has a sophisticated search interface, data collection could be performed with relatively little efforts. When computing the impact factor [for a basic introduction please see 17] and the immediacy index for the Scopus journals, we used the same formulas as in the JCR. Attention has to be paid to the fact that the impact factor (and the immediacy index) only considers research and review articles. As a consequence, we limited our search statements to these document types. In order to determine if there are high impact pharma journals which are not included in the JCR, we used journal lists provided by Science Direct and Subito.
All data were collected in November 2006.
Findings
The presentation of the results follows the research questions outlined above.
Coverage of JCR high impact pharmacology and pharmacy journals in Scopus
A comparison of journals from a certain subject category between the two databases is not without problems for various reasons. Usually different databases use different classification systems. While the relevant subject category is "pharmacology, toxicology and pharmaceutics" in Scopus, the Web of Science uses two categories ("pharmacology & pharmacy" and "toxicology"). Furthermore, the different size of the databases must be considered. While there were 193 journals included in the subject category "pharmacology & pharmacy" (and 75 partly overlapping "toxicology" journals) in the JCR, Scopus covered altogether 2 266 active titles. (This confirms previous studies [e.g. 2, 7, 12] according to which Scopus has a strong concentration on health and life sciences.) As a consequence, the coverage of JCR journals in Scopus is broader than contrariwise. It was not expected, however, that each of the top-100 JCR pharmacy journals (ranked by impact factor) was included in Scopus.
Finally the indexing procedure is not consistent in different databases. 96 journals were indexed as pharma journals in both citation indices. The remaining four journals were assigned to other categories in Scopus ("medicine" and "biochemistry, genetics and molecular biology"). Since there are more journals included in Scopus than in WOS, a journal in Scopus has a higher chance to get cited in general. Therefore the values for the impact factor and the immediacy index should also be higher in Scopus. This assumption turned out to be true for most journals in our journal sample. The impact factor was higher for 82 journals in Scopus, 18 journals had a higher impact factor in the JCR. Similarly the immediacy index of 78 journals had higher values in Scopus. As can be seen in Table 1 , a journal with a high impact factor in the JCR usually has a high impact factor in Scopus, and vice versa. This goes along with the correlation (Pearson's r=0.96) of the impact factors of the top-100 pharma journals in the JCR and those computed for them in Scopus.
The size of the differences (in %) between the impact factor values follows a skewed distribution (see Table  2 ). For most journals, the difference is relatively small (median = 10.3%). Yet two journals ("Reviews of Physiology Biochemistry and Pharmacology" and "AAPS Pharmsci") attracted our attention because of their remarkable discrepancies of 74 and 146 percent. A first analysis shows that these big differences are not only caused by different citation frequencies but also by high deviations in the numbers of articles. In order to identify the reasons for these differences, we will go into deeper analysis in the following sub-section (reliability of data). Table 2 also confirms the original assumption that higher citations in Scopus, which are generated by more (pharma) journals in this database, are the main cause for the higher impact factor values. The median of the percentage differences between Scopus and the JCR in the impact factor (10. The higher differences in the immediacy index (median = 23.4 %) are also mainly due to greater deviations in the number of citations which articles published in 2005 have received in the same year (median = 24.5 %). However, it must be taken into account that, because the number of citations in the year in which these articles were published is low in general, already small deviations in the absolute numbers can show high percentage effects. As was pointed out by one of the referees, "Molecular Pharmacology" is an extreme example. The reason for the huge difference in the immediacy index for this journal (nearly 8800% -see Table 3 ) is due to an error in the JCR. While a search in WOS showed 413 citations in the year 2005 to articles published in the same year, the JCR lists only 6 citations. As a consequence, the immediacy index ought to be corrected to 0.93 in the JCR resulting in a much smaller difference in comparison with the corresponding value computed in Scopus. 
Reliability of data
Contrary to the citations received, there should be only small differences in the number of articles between the two databases. Since Pipp [9, p. 13] reported differences in the provision of document types between the two databases which may strongly affect the number of retrieved records, we considered only articles and review articles. As can be seen in Table 2 , the values for the median of the percentage differences are between 1.6 and 2.1% in the three years. The difference in the number of research and review articles is below 5% for two thirds of all journals in each year. Nevertheless, we computed a wider difference of at least 10 percent for one fifth of all journals. There were even a few journals in each year, in which the article counts differed more than 50% (2003: "Reviews of Physiology Biochemistry and Pharmacology", "Pharmacogenomics", "Drug Discovery Today", 2004: "Reviews of Physiology, Biochemistry and Pharmacology", "Drug News & Perspectives", "AAPS Pharmsci", 2005: "Nature Reviews Drug Discovery", "CNS Drug Reviews", "European Journal of Pharmaceutical Sciences", "Drug News & Perspectives"). This raises severe questions with regard to data quality. In the following, we go into more details about the discrepancies of the two journals identified in the previous section. As is revealed by Table 4 , the article counts in Scopus are accordant with the real values we collected for "Reviews of Physiology, Biochemistry and Pharmacology". However, there are big deviations in the article numbers for this hybrid serial in comparison with the Web of Science. The main reason for this mismatch might be the irregular publication of this serial. Accordingly, a few volumes were not indexed in the proper publication year in WOS. As can also be seen in Table 4 , there are again data inconsistencies between JCR and WOS for the year 2005. For the electronic journal "AAPS PharmSCI" (see Table 5 ) the JCR article data of the year 2003, which are used for the calculation of the impact factor, are again erroneous (22 instead of 32 articles) and not consistent with the WOS figures (31 articles). However, the indexing in JCR and WOS is nearly correct in the following years. Contrary to WOS, the title change (from "AAPS PharmSCI" to "AAPS J") affected Scopus more negatively. In particular it is not very clear which articles refer to which journal title. For instance, a search for the former title ("AAPS PharmSCI") in 2005 shows 76 articles and review articles assigned to "AAPS J". However, a search for "AAPS J" in the same year lists only one article for this title (but 48 items for "AAPS Journal Electronic Resource").
For most other journals, the mismatch in the article counts was due to the different assignment to document types. For instance, various conference papers in "Drug Discovery Today", "Drug News & Perspectives" and "CNS Drug Reviews" were categorized as articles in Scopus; in WOS they were nonexistent. For two other journals ("Nature Reviews Drug Discovery" and "Pharmacogenomics") opinion papers were attributed to articles in Scopus but to editorial comments in WOS. And in the "European Journal of Pharmaceutical Sciences" meeting abstracts were wrongly assigned to articles in Scopus. As this short analysis reveals, both Scopus and WOS have problems with regard to the accuracy of data. Unlike Deis and Goodman [4, 5] , our analysis suggests that Scopus is not worse than the Web of Science with regard to the completeness of (research and review) articles in journals. It must be considered, however, that our analysis was based on a small, more specialized and more present journal sample.
Gorraiz and Schloegl

Pharmaceutical journals covered by Scopus but not included in the JCR
In order to identify other high impact pharmaceutical journals not covered by the JCR, it would be easiest to compare the highest impact journals in Scopus with their counterparts in JCR. Though Scopus offers sophisticated tools for citation analysis, there are no citation statistics and rankings comparable with the JCR in this database as of now. As a consequence, the compilation of the high impact journals in this database can be rather laborious and time-consuming. For this reason we contacted Elsevier which provided us with the citation counts and number of articles for journals from the subject category "pharmacology, toxicology and pharmaceutical science" in Science Direct. After having checked the reliability of data for these 81 journals in Scopus (in case of data inconsistencies we used the Scopus data), we calculated the impact factor and the immediacy index and compared them with the results in JCR. As can be seen in Table 6 , 10 out of 81 titles were not covered by JCR in the year 2005. For each of these journals, we computed a relatively low impact factor. Only one Science Direct journal ("NeuroRX"), with an impact factor amounting to 2.261, would place in the JCR top 100 ranking. For four titles ("Acute Pain", "The American Journal of Geriatric Pharmacotherapy", "Journal of Clinical Forensic Medicine" and "Legal Medicine") an impact factor was calculated which would rank these journals better than the worst ranked (193rd) JCR pharma journal. The impact factor of the other five journals could not be computed because of publication or indexing irregularities.
From the remaining 71 journals, 40 were covered under the subject categories "pharmacology and pharmacy", 10 under "toxicology" and 21 under other categories such as "medicine" in JCR. 31 of the 40 titles were among the JCR top 100 pharma journals, i.e. almost one third of the JCR top 100 pharmaceutical journals are currently published by Elsevier and are available in full text via Science Direct. Four of these journals are in the top 10, with "Trends in Pharmacological Sciences" ranked best in fifth position. Comparing the impact factors between Scopus and JCR revealed again that most journals have a higher value for this indicator in the Scopus database. Also the distribution of the differences (in percent) is similar.
In order to determine further "candidates" for important journals, we tied up to the results of a study by Schloegl and Gorraiz [18] which showed a low to moderate correlation between the journal requests at a document delivery service and the citation frequencies of those journals in the JCR. Accordingly, we used data from Subito [19] , one of the largest European document delivery services, and examined highly demanded journals for inclusion in JCR and Scopus. Our comparison revealed that from the top 100 JCR journals (subject category "pharmacology and pharmacy") 60 titles were among the 1000 most requested journals in Subito. Furthermore, we identified three Subito journals ("Current Pharmaceutical Biotechnology", "Pediatric Drugs", and "Expert Opinion on Drug Safety") which were included in Scopus but not in JCR. The computed impact factors in Scopus amounted to 2.578, 2.188 and 1.798. This would place them 59th, 78th and 103rd in the JCR ranking.
Conclusions
The most relevant implications of our study can be resumed as follows:
Coverage:
Our analysis showed that both WOS and Scopus have a good coverage of high impact journals in the field of pharmacology and pharmacy. We could identify a few pharmaceutical journals with a significant but not top impact factor which were not included in the JCR. We computed higher values for both impact factor and immediacy index for most journals in Scopus. This is mainly due to the fact that there are more sources in Scopus which generate higher citations in this database and confirms that Scopus is the world's largest multidisciplinary database in terms of more recent scholarly literature (the back files of the Web of Science go back much further to the past).
Subject categories:
The subject categorisation is not very extensive in either database. Furthermore, the assignment of subject categories to journals is not always transparent and differs between Scopus and WOS. This can lead to more or less considerable differences when comparing the two databases. Obviously, a more detailed subject categorisation and a better journal classification would improve the quality of the two databases.
Document types:
Another implication of our study is that Scopus and the Web of Science provide different document types and that they do not assign them always consistently. As our analysis has shown, a different assignment to document types was one of the main reasons for mismatches in the number of (research) articles.
Reliability of data:
The differences in the number of research and review articles were tolerable for the majority of the investigated journals. Nevertheless, we calculated greater differences for several journals which were caused by both Scopus and WOS. Furthermore, data consistency between WOS and JCR cannot be taken for granted. In cases where data accuracy is crucial, it is advisable to verify the data.
Appropriateness for bibliometric analyses:
In our study, Scopus turned out to be suitable for bibliometric analyses. However, the practicability of such studies could be much increased if Scopus were to add an own bibliometric "infrastructure" comparable to the Journal Citation Reports to its citation database. Since such an add-on could be implemented from scratch, critical issues concerning the JCR could be avoided from the beginning. Among other issues [see e.g. 20], this applies to field-normalized journal impact indicators [e.g. 21, p. 1993f.] . Furthermore, it could be avoided to mix different document types when relating the citation frequencies to the article counts [e.g. 22, 23] . Concerning conference articles, Scopus is more transparent than the Web of Knowledge. For the latter it is not always clear in which cases proceedings, which are recorded in ISI Proceedings in general, are included.
